Prognostic Role of p53 Immunohistochemical Status in invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors-Reference-Cited by-同舟云学术

Prognostic Role of p53 Immunohistochemical Status in invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors

Published:2023-11-23 Issue: Volume: Page:
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Dajti Gerti¹,Serra Margherita¹,Cisternino Giovanni²,Ceccarelli Claudio³,Pellegrini Alice¹,Melina Marica¹,De Leo Antonio³,Santini Donatella⁴,Taffurelli Mario¹,Zanotti Simone¹

Affiliation:

1. Breast and General Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna , Italy

2. Surgical Pathology Unit, IRCCS Ospedale San Raffaele di Milano , Milan , Italy

3. Department of Experimental, Diagnostic and Specialty Medicine–DIMES, Alma Mater Studiorum University of Bologna , Bologna , Italy

4. Surgical Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna , Italy

Abstract

Abstract Purpose The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer

Funder

Italian Ministry of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad309/53706439/oyad309.pdf

Reference33 articles.

1. Prospective validation of a 21-gene expression assay in breast cancer;Sparano,2015

2. 70-gene signature as an aid to treatment decisions in early-stage breast cancer;Cardoso,2016

3. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer;Lænkholm,2018

4. Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy;Buus,2016

5. p53 has a direct apoptogenic role at the mitochondria;Mihara,2003